Thus the assay can be used for the routine investigation to see the presence of the NUP98::NSD1 fusion transcript for newly admitted patients, specifically AML patients showing the FLT3-ITD and not responding to induction therapy. This evidence concerns the gene NUP98 and acute myeloid leukemia.